Skip to main content
. 2017 Feb 1;7:41358. doi: 10.1038/srep41358

Figure 4. Zoledronic acid prevents Clomipramine-induced bone loss.

Figure 4

. WT mice were treated with Zoledronic acid (n = 6) or saline (n = 5) or for 14 days followed by Clomipramine for an additional 14 days. In a separate group, mice were treated with water (vehicle for Clomipramine) for 14 days (n = 4) followed by saline (vehicle for Zoledronic acid) for an additional 14 days. Mice were sacrificed 4 hours after last injection. (a) Tibiae were subjected to μCT. (b) H&E and TRAP-stained tibial sections and histomorphometric analysis of BV/TV (%) and OC.N/BS (#/mm). Values are mean ± S.D. of 4–6 mice/group. *p < 0.05 versus Ctrl and CLP + ZA-treated groups. Scale bars: 500 μm in upper and 50 μm in lower panel in (b). Vehicle + CLP: saline + CLP, ZA + CLP: Zoledronic acid + Clomipramine, Ctrl: water + saline.